Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer

Dora, David; Rivard, Christopher J.; Yu, Hui; Pickard, Shivaun Lueke; László, Viktória; Harkó, Tünde; Gerdán, Csongor; Dinya, Elek; Höetzenecker, Konrad; Hirsch, Fred R.; Lohinai, Zoltán; Döme, Balázs

doi:10.1007/s00262-022-03270-w

Cited by 10 publications

(7 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most CD68+ TAMs are M2-polarised, and express CD163 in neuroendocrine (NE)-low tumor subsets, creating an immunosuppressive microenvironment peculiarly inside tumor nests (21). In addition, a previous study has confirmed that the presence of CD68+ TAMs in tumor nests was significantly detrimental to OS (22). These studies related to small cell lung cancer strongly support our conclusions.…”

Section: Correlations Between Tim-3 Expression In Tams and The Clinic...supporting

confidence: 88%

Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study

Zhang¹,

Xu²,

Ma³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) is considered a key negative regulator in T-cell-mediated response. However, few studies have been reported on the relationship between TIM-3 expression in tumor-associated macrophages (TAMs) and clinicopathological characteristics of patients. This study evaluated the correlation between the expression of TIM-3 on the surface of TAMs macrophages in tumor matrix and the clinical outcome of patients with non-small cell lung cancer (NSCLC). Methods:The expression of CD68, CD163 and TIM-3 in 248 NSCLC patients who underwent surgery in Zhoushan Hospital from January 2010 to January 2013 was detected by immunohistochemistry (IHC). From the date of operation to the date of death, overall survival (OS) was measured to analyze the relationship between the expression of Tim-3 and the prognosis of NSCLC patients. Results:The study assessed 248 patients with NSCLC. TIM-3 expression in TAMs was more frequently identified in patients with higher carcinoembryonic antigen (CEA) levels, lymph node metastasis, higher grade, high CD68 expression, and high CD163 expression (P<0.05). The OS of the high TIM-3 expression groups was shorter than that of the low TIM-3 expression groups (P=0.01). Patients with high TIM-3 and CD68/CD163 expressions had the worst prognosis, whereas patients with low expressions of both TIM-3 and CD68/CD163 had the best prognosis (P<0.05). In NSCLC, the OS of the high TIM-3 expression groups was shorter than that of the low TIM-3 expression groups (P=0.01). In lung adenocarcinoma, the OS of the high TIM-3 expression groups was shorter than that of the low TIM-3 expression groups(P=0.03).Conclusions: TIM-3 expression in TAMs may be a promising prognostic biomarker for NSCLC or adenocarcinoma. Our results demonstrated that high TIM-3 expression in TAMs was an independent predictor of worse prognosis in patients.

show abstract

Section: Correlations Between Tim-3 Expression In Tams and The Clinic...supporting

confidence: 88%

Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study

Zhang¹,

Xu²,

Ma³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Additionally, we screened the risk-related DEGs and identified NEUROD1 as a novel biomarker in PaCa. NEUROD1 has been identified as a subtype marker in neuroendocrine tumors, especially small-cell lung cancer ( Dora et al, 2022 ). However, NEUROD1 is also revealed to express in other tumor cells and play a significant role in tumor progression.…”

Section: Discussionmentioning

confidence: 99%

NEUROD1 predicts better prognosis in pancreatic cancer revealed by a TILs-based prognostic signature

et al. 2022

View full text Add to dashboard Cite

It has been well-defined that tumor-infiltrating lymphocytes (TILs) play critical roles in pancreatic cancer (PaCa) progression. This research aimed to comprehensively explore the composition of TILs in PaCa and their potential clinical significance. A total of 178 samples from the TCGA and 63 samples from the GSE57495 dataset were enrolled in our study. ImmuCellAI was applied to calculate the infiltrating abundance of 24 immune cell types in PaCa and further survival analysis revealed the prognostic values of TILs in PaCa. Moreover, the Hallmark enticement analysis of differentially expressed genes (DEGs) between low- and high-risk groups was performed as well. Immunohistochemistry staining was used to evaluate NEUROD1 expression. As result, different kinds of TILs had distinct infiltrating features. In addition, Specific TILs subsets had notable prognostic values in PaCa. We further established a 6-TILs signature to assess the prognosis of PaCa patients. Kaplan-Meier and Cox regression analyses both suggested the significant prognostic value of the signature in PaCa. Based on the prognostic signature, we screened a great deal of potential prognostic biomarkers and successfully validated NEUROD1 as a novel prognostic biomarker in PaCa. Overall, the current study illuminated the immune cells infiltrating the landscape in PaCa and identified a TILs-dependent signature and NEUROD1 for prognostic prediction in PaCa patients.

show abstract

“…High STING expression and immune cell infiltration are associated with prolonged survival in SCLC patients. Furthermore, STING activators can trigger anti-tumor adaptive immunity by reprogramming pro-tumor M2 macrophages into an anti-tumor phenotype [ 118 , 119 ].…”

Section: Association Of Tams With Lung Cancer Treatmentmentioning

confidence: 99%

Tumor-associated macrophages affect the treatment of lung cancer

Yu,

Zou,

2024

Heliyon

View full text Add to dashboard Cite

Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer

Cited by 10 publications

References 60 publications

Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study

Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study

NEUROD1 predicts better prognosis in pancreatic cancer revealed by a TILs-based prognostic signature

Tumor-associated macrophages affect the treatment of lung cancer

Contact Info

Product

Resources

About